flornaptitril-pet-phase-3-nct06254469

Flornaptitril PET Phase 3 (NCT06254469)

Overview

Flornaptitril PET Phase 3 (NCT06254469)

Overview

This Phase 3 clinical trial evaluates [F-18]Flornaptitril, a novel second-generation tau positron emission tomography (PET) tracer, for its ability to predict Alzheimer's disease (AD) progression and differentiate chronic traumatic encephalopathy (CTE) from AD. Developed by CereMark Pharma, Flornaptitril represents a significant advancement in tau imaging technology designed to address the diagnostic challenges that have limited first-generation tau PET tracers["@smith2020"].

The trial aims to establish Flornaptitril as a definitive diagnostic tool for differentiating between AD and CTE, two conditions with overlapping clinical presentations but fundamentally different treatment approaches. This differentiation has historically required invasive post-mortem examination, making in vivo detection a critical unmet need in clinical neurology.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06254469 |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | CereMark Pharma |
| Estimated Enrollment | 230 participants |
| Study Start | 2025 |
| Estimated Completion | 2028 |
| Study Design | Multi-center, cross-sectional imaging study |
| Primary Outcome | Diagnostic accuracy for AD vs. non-AD |
| Secondary Outcomes | CTE vs. AD differentiation, sensitivity, specificity |

Study Arms

| Arm | Population | Assessment |
|-----|-------------|------------|
| 1 | Confirmed AD | Flornaptitril PET, MRI, cognitive testing |
| 2 | Suspected CTE | Flornaptitril PET, MRI, cognitive testing |
| 3 | Cognitively normal | Flornaptitril PET, MRI, cognitive testing |
| 4 | Other dementia | Flornaptitril PET, MRI, cognitive testing |

Study Sites

The trial will be conducted at leading academic medical centers with expertise in PET imaging and neurodegenerative disease:

• Leading US memory disorders centers
• Specialized CTE research centers
• Academic nuclear medicine departments

Background and Rationale

Limitations of Current Tau PET Tracers

First-generation tau PET tracers, while revolutionary, have significant limitations that have constrained their clinical utility[@jack2023]:

| Limitation | Description | Impact |
|------------|-------------|--------|
| Off-target binding | Binding to melanin-containing cells, monoamine oxidase | False positive signals |
| Limited specificity | Cannot distinguish AD from other tauopathies | Diagnostic uncertainty |
| CTE detection gap | No validated tracer for CTE | Unable to diagnose CTE in vivo |
| Subcortical binding | Limited detection in deeper brain structures | Incomplete disease assessment |
| Late detection | Detects only established pathology | Misses early-stage disease |

Second-Generation Tracer Development

Flornaptitril was specifically designed to address these limitations[@marquez2023]:

Design Improvements:

• Optimized binding site: Targets unique epitopes on aggregated tau
• Reduced off-target: Minimized affinity for melanin and MAO
• CTE-specific patterns: Detection of CTE-typical tau distributions
• Early detection: Sensitivity to lower levels of tau pathology
• Improved kinetics: Faster uptake and clearance

Clinical Need for CTE Differentiation

Chronic traumatic encephalopathy represents a critical diagnostic challenge[@dickstein2020]:

CTE Overview:

• Pathology: Progressive tauopathy following repetitive traumatic brain injury
• Clinical presentation: Cognitive decline, behavioral changes, motor symptoms
• Diagnosis: Currently only confirmed post-mortem
• Prevalence: Estimated 10-30% of contact sport athletes

• Symptoms overlap with AD, frontotemporal dementia, and psychiatric disease
• No definitive in vivo diagnostic test
• Different treatment approaches required
• Implications for prognosis and management

Scientific Rationale

Tau Pathology in Alzheimer's Disease

Tau protein is a microtubule-associated protein that, when hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), one of the hallmark pathologies of Alzheimer's disease:

Tau Biology:

• Normal function: Stabilizes microtubules, supports axonal transport
• Hyperphosphorylation: Abnormal phosphorylation leads to aggregation
• NFT formation: Paired helical filaments accumulate as NFTs
• Spread: Pathologic tau propagates through neural networks

• Regional tau burden correlates with cognitive impairment
• Tau accumulation follows predictable staging (Braak stages)
• Individual NFT burden predicts clinical progression
• Tau PET more closely tracks clinical decline than amyloid PET

Tau PET in Alzheimer's Disease Diagnosis

Tau PET imaging has transformed AD research and clinical practice[@moghekar2021]:

Diagnostic Applications:

• Differential diagnosis: Distinguishing AD from other dementias
• Disease staging: Braak stage determination in vivo
• Prognostication: Predicting progression rate
• Treatment monitoring: Assessing anti-tau therapy effects
• Trial enrichment: Identifying tau-positive participants

• Flortaucipir (AV-1451, Tauvid): FDA-approved, first-generation
• MK-6240 (Florquinitau): Second-generation, improved properties
• RO-948: Reduced off-target binding
• PBB3 (APN-1607): Broader tau isoform binding

CTE and Tau Pathology

Chronic traumatic encephalopathy represents a distinct tauopathy with characteristic pathology[@collins2022]:

CTE Pathologic Features:

• Location: Predominant involvement of cortical sulcal depths
• Pattern: Perivascular distribution of NFTs
• Tau isoform: Primarily 3R/4R tau aggregates (like AD)
• Distribution: Focal and patchy, unlike AD's hierarchical spread

• More prominent in superficial cortical layers
• Perivascular accentuation
• Less consistent with Braak staging
• Variable distribution across brain regions

• Clinical features overlap with AD and other dementias
• No validated antemortem diagnostic test
• History of TBI is necessary but not sufficient
• Definitive diagnosis requires post-mortem examination

Study Design

Imaging Protocol

The Flornaptitril PET imaging protocol follows established standards for tau PET:

Radiotracer Administration:

• Dose: 185-370 MBq (5-10 mCi) intravenous injection
• Specific activity: ≥95% radiochemical purity
• Formulation: Ready-to-use solution

• Duration: 90 minutes dynamic acquisition
• Frames: 6 × 5 min frames from 30-90 min
• Motion correction: Frame-by-frame alignment
• Attenuation correction: CT-based attenuation map

• Reconstruction: OSEM with point spread function
• Normalization: Standardized uptake value (SUV)
• Reference region: Cerebellar gray matter
• Analysis: SUVR with region-of-interest quantification

MRI Co-registration

High-resolution MRI provides anatomical localization:

• Sequence: T1-weighted MPRAGE or equivalent
• Resolution: 1mm isotropic
• Co-registration: PET-MRI rigid alignment
• Segmentation: Automated parcellation

Cognitive Assessment

Comprehensive neuropsychological testing battery:

• Memory: Rey Auditory Verbal Learning Test, Benson Figure
• Executive: Trail Making Test, Wisconsin Card Sorting
• Language: Boston Naming Test, Semantic Fluency
• Visuospatial: Clock Drawing, Block Design
• Global: MMSE, MoCA, CDR

Outcome Measures

Primary Endpoints

• Sensitivity and specificity for AD detection
• Receiver operating characteristic (ROC) analysis
• Comparison to clinical diagnosis as gold standard

• Regional tau burden in predefined regions
• Composite neocortical SUVR
• Regional distribution patterns

Secondary Endpoints

• Pattern analysis for CTE-typical distribution
• Sulcal depth involvement score
• Perivascular pattern detection

• Association between SUVR and cognitive performance
• Domain-specific correlations
• Predictive value for future decline

• Correlation with CSF total tau and p-tau181
• Correlation with plasma p-tau217 and p-tau181
• Comparison with amyloid PET

• Change in SUVR over 2-year follow-up
• Rate of tau accumulation prediction
• Correlation with clinical progression

Safety Endpoints

• Adverse events monitoring
• Radiation dosimetry assessment
• Vital signs and laboratory values
• ECG changes

Participant Populations

Alzheimer's Disease Cohort

Inclusion Criteria:

• Age 50-85 years
• Clinical diagnosis of probable AD (NIA-AA criteria)
• Positive amyloid PET or CSF biomarkers
• MMSE 16-26 (mild to moderate dementia)
• Available informant/caregiver

• Other neurological conditions
• Significant psychiatric illness
• Contraindications to MRI/PET

CTE Cohort

Inclusion Criteria:

• Age 30-75 years
• History of repetitive traumatic brain injury
• Clinical features suggestive of CTE
• Cognitive or behavioral symptoms

• Confirmed AD or other dementia
• Active litigation (settlement pending)

Cognitively Normal Controls

Inclusion Criteria:

• Age 50-85 years
• Normal cognitive testing
• No significant neurological history
• Willing to undergo all procedures

Clinical Significance

Diagnostic Applications

If successful, Flornaptitril PET will enable:

• Detect tau pathology before significant cognitive decline
• Enable earlier treatment intervention
• Improve prognostic counseling

• First validated in vivo CTE diagnostic test
• Enable appropriate clinical management
• Support research on CTE prevalence

• Distinguish AD from other dementias
• Identify mixed pathology cases
• Guide treatment selection

• Objective measurement of disease severity
• Track disease progression
• Inform clinical management

Research Applications

The trial will support:

• Identify tau-positive participants
• Stratify by disease stage
• Monitor treatment response

• Validate PET against fluid biomarkers
• Establish cutoff values for diagnosis
• Create reference databases

• Study tau spread in vivo
• Test mechanistic hypotheses
• Develop propagation models

Competitive Landscape

Tau PET Tracers in Development

| Tracer | Company | Stage | Key Features |
|--------|---------|-------|---------------|
| Flornaptitril | CereMark | Phase 3 | CTE differentiation |
| MK-6240 | Merck/NIH | Phase 3 | Second-generation |
| RO948 | Roche | Phase 2/3 | Low off-target |
| PBB3 | Aprinoia | Phase 2 | 3R/4R detection |
| APN-1607 | Aprinoia | Phase 3 | Broader binding |

Flornaptitril Positioning

Unique Value Proposition:

• First tracer specifically designed for CTE detection
• Optimized for AD/CTE differentiation
• Second-generation improvements over Flortaucipir
• Novel binding profile

Safety Profile

Based on Phase 1/2 data, Flornaptitril shows:

Expected Adverse Events

• Common: Headache, injection site discomfort
• Rare: Mild nausea, dizziness

Contraindications

• Pregnancy or breastfeeding
• Severe renal impairment (radiotracer excretion)
• Active infection

Monitoring

• Vital signs pre- and post-injection
• 24-hour follow-up call
• Adverse event collection through study completion

Future Directions

Registration and Approval

If Phase 3 is successful:

• FDA approval expected 2029-2030
• CMS coverage determination
• Integration into diagnostic algorithms

Clinical Implementation

Potential applications:

• Memory disorder clinics
• CTE specialty centers
• Research institutions
• Clinical trial sites

Combination Approaches

Future development:

• Amyloid/tau PET combined imaging
• PET-MRI integrated diagnostics
• Fluid biomarker correlation

Cross-References

• [Tau PET Imaging](/technologies/tau-pet-imaging)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Chronic Traumatic Encephalopathy](/diseases/cte)
• [Neurofibrillary Tangles](/diseases/neurofibrillary-tangles)
• [Tauopathies](/diseases/tauopathies)
• [Brain Trauma and Neurodegeneration](/mechanisms/tbi-neurodegeneration)
• [Tau Propagation](/mechanisms/tau-propagation)

External Links

• [ClinicalTrials.gov NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
• [CereMark Pharma](https://www.ceremarkpharma.com/)
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
• [CTE Center Boston University](https://www.bu.edu/cte/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References